Category: Health

Categories
Health

Pfizer Vaccine Is Extremely Efficient In opposition to Variants, Research Discover

Pfizer Vaccine Is Highly Effective Against Variants, Studies Find

The second new study, published in The Lancet, was carried out by researchers from the Israel Ministry of Health and Pfizer. It is based on more than 230,000 coronavirus infections that occurred in Israel between January 24th and April 3rd. During that period, B.1.1.7 accounted for nearly 95 percent of all coronavirus cases in the country, with more than half of which vaccinated its population.

The researchers found that the vaccine was more than 95 percent effective against coronavirus infections, hospitalizations, and deaths in people aged 16 and over who were fully vaccinated. It also worked well in older adults. Among those 85 years old or older, the vaccine was more than 94 percent effective against infection, hospitalization, and death.

As the percentage of people fully vaccinated increased in each age group, the incidence of coronavirus infections decreased in this cohort, the researchers found. The decline in infection rates was more in line with the timing of increases in vaccine coverage in each age group than the start of a nationwide lockdown. The results suggest that Israel’s rapid pace of vaccination was responsible for the decline in infections in the country.

“I’m just so happy to see this data that these vaccines have such an amazing impact on controlling infection and disease in the real world,” said Akiko Iwasaki, an immunologist at Yale University.

Both studies also reported that two doses of the vaccine provided significantly more protection than one dose. For example, in the Israel study, one dose of the vaccine was 77 percent effective against death, while two doses were 96.7 percent effective.

“It absolutely underscores the need for the second dose,” said Dr. Kathleen Neuzil, who directs the Center for Vaccine Development and Global Health at the University of Maryland School of Medicine.

Taken together, the studies suggest that vaccination remains a plausible way out of the pandemic even with the new variants, experts said. “If we can get vaccines out into the world and improve reporting,” said Dr. Neuzil, “I believe that we can go beyond that and stay up to date on the emergence of new variants.”

Categories
Health

Moderna says vaccine generates promising immune response in opposition to variants

Moderna says vaccine generates promising immune response against variants

A doctor draws a syringe of Moderna’s vaccine.

Oliver Berg | Image Alliance | Getty Images

A booster of Moderna’s Covid-19 vaccine triggered a promising immune response against variants B.1.351 and P.1, which were first identified in South Africa and Brazil, respectively, the company announced on Wednesday, citing early data from an ongoing clinical study.

In the study, Moderna is testing a 50 microgram dose of its vaccine in previously vaccinated people. The booster dose was found to increase neutralizing antibody responses against the original virus, as well as against B.1.351 and P.1, two variants that have since spread to other countries, including the United States

The company also said that a booster shot of its other vaccine, which it calls mRNA-1273.351, produced an even better immune response over its current vaccine against the B.1.351 variant from South Africa. The new vaccine is a variant-specific booster shot that targets B.1.351.

The preliminary results, which Moderna says will be published online, have not yet been peer-reviewed.

“As we seek to defeat the ongoing pandemic, we continue to seek to be proactive as the virus evolves,” said Stephane Bancel, CEO of Moderna, in a press release. “We are encouraged by this new data, which increases our confidence that our booster strategy should protect against these newly discovered variants.”

According to Moderna, the side effects were similar to those seen after the second dose of the vaccine in the previously reported studies. Side effects included injection site pain, fatigue and headache, and muscle and joint pain.

The new data comes as drug makers and scientists now say people will likely need a booster shot of Covid-19 vaccines and possibly additional shots each year, just like they did with seasonal flu.

Moderna’s vaccine requires two doses four weeks apart. As with Pfizer and Johnson & Johnson, the shot against Covid is very effective, although company executives and officials now say they expect this strong protection to wear off over time. Pfizer’s vaccine is also a two-dose therapy, while the J&J immunization is just one burst.

The Chief Medical Officer of the White House, Dr. Anthony Fauci, previously said that Americans may need booster vaccinations to better protect themselves from variants.

Earlier Wednesday, US health officials said highly contagious variants are still a “wild card” in their nationwide campaign to vaccinate most American adults by July 4th.

A report by the Centers for Disease Control and Prevention published on Wednesday predicted that Covid-19 cases will increase until May due to the highly contagious variant B.1.1.7 first identified in the UK, before declining sharply by July, because vaccinations reduce infections. Still, variants threaten to reverse the nation’s progress, officials said,

“We are seeing that our current vaccines protect against the pollutants circulating in the country. Put simply, the sooner more people are vaccinated, the sooner we will all get back to normal,” said CDC Director Dr. Rochelle Walensky during a Covid press conference at the White House.

Moderna is evaluating three approaches to increasing immunity. The first approach would use variant-specific booster vaccinations such as mRNA-1273.351, but at a lower dose than the original vaccine. The second would combine the original vaccine with a variant-specific vaccine into a single shot at 50 micrograms or less, Moderna said. The third would test a third shot of the original vaccine at a lower dose.

Bancel told CNBC last month that the company is hoping to have a booster shot for its two-dose vaccine in the fall.

Categories
Health

New Covid Instances in Arizona Are Up 21 P.c in Two Weeks

New Covid Cases in Arizona Are Up 21 Percent in Two Weeks

While most of the United States has seen a steady decline in new coronavirus cases recently, Arizona was an outlier.

The state has not been inundated with another wave of the virus, but public health experts are concerned about a steady increase in cases and hospitalizations. As of Tuesday, Arizona’s daily average was up 19 percent in the past two weeks, the second largest increase in the nation over that period after Wyoming. Only four other states reported increases of more than 10 percent during this period: Washington, Hawaii, Arkansas and Oregon.

The daily number of new cases in Arizona is 10 per 100,000 people, still below the national average of 14 per 100,000. In the past 14 days, the country has seen a 26 percent decrease in new coronavirus cases, and 27 states have seen a 15 percent or more decrease in new coronavirus cases, according to a New York Times database.

Will Humble, a former state health director who heads the Arizona Public Health Association, attributed the spike in new cases to several factors, including a spring influx of travelers and the spread of a variant of the virus first discovered in the UK. Variant B.1.1.7 was associated with increased transferability.

Mr Humble said the Arizona surge likely wouldn’t result in a significant increase in deaths, which have declined in the state. Most older adults and other people in the state who are at increased risk of developing serious illnesses have already been vaccinated, while those in their twenties, thirties, and forties who are more likely to have new infections are more likely to be.

Mr Humble said the surge in cases had “very different public health implications” than it did a few months ago, when far fewer people were vaccinated.

“We’re not going to have the kind of deadly experiences we’d have in December, January or February,” said Humble. Even so, there has been “a remarkable upward movement” in hospital and intensive care units.

Arizona was slow to put restrictions in place last summer and was quick to remove them as falls have skyrocketed and ICU beds are nearly full. From early June to mid-July, the state reported new cases at the highest rate in the country for its size, peaking at 3,800 per day.

In January, Arizona again had its highest daily incidence rate in a while. At one point it was averaging over 8,000 a day, more than double that of the summer summit.

Governor Doug Ducey signed an executive order in March that lifted all Covid-19 restrictions in the state and prevented local governments from issuing mask mandates.

Mr Humble said politics may have made Arizona more vulnerable: “There is no mitigation here at all, and it has not been in months,” he said.

About 41 percent of Arizonans received a first dose of the vaccine, and 30 percent were fully vaccinated, just below the national average. However, the picture varies greatly from country to country. Three of Arizona’s 15 counties vaccinated more than 40 percent of residents, but five vaccinated less than 30 percent as of Tuesday.

Dr. Cara Christ, the director of the Arizona Department of Health, said last month that the initial rush for vaccines had slowed significantly. “Before, vaccine appointments were made almost immediately as soon as they were available,” she said. “The time has come now that it is possible to make an appointment on the same day at practically every state location.”

Categories
Health

Theranos blood take a look at accuracy at coronary heart of Elizabeth Holmes legal case

Theranos blood test accuracy at heart of Elizabeth Holmes criminal case

Former Theranos CEO Elizabeth Holmes will attend the US government fraud court hearing against her on May 5, 2021.

CNBC

Former Theranos CEO Elizabeth Holmes promised a technological breakthrough, but it really was a house of cards, prosecutors said during a trial Wednesday.

“Miss Holmes went out, told the world, and told investors, we have tests with the highest accuracy rate,” said US assistant attorney Robert Leach, adding that her expert’s testimony “lies.”

The argument was in response to efforts by the defense, Dr. Stephen Master, an associate professor of pathology and laboratory in the University of Pennsylvania Medical School, from taking a stand. In 2013, after interviewing Holmes at a conference, Master said that her claims about Theranos’ miniLab technology “fell far short of previous claims”.

Holmes’ defenders argued that the master was used as a “parrot” by the government and that his conclusions about certain Theranos blood tests were “based on emails and customer complaints,” not practical experience.

Wednesday’s hearing was the second day of the argument about what evidence can be admitted and excluded from Holmes’ criminal fraud trial, which begins August 31st.

Prosecutors, among other things, alleged that Holmes was presenting an inappropriate defense in good faith.

“Efforts to return money to victims cannot undo the fraud once it is committed,” said John Bostick, another US assistant attorney.

The judge is expected to rule on critical motions, including whether to provide evidence of Holmes’ assets and expenses, private text exchanges and regulatory reports by the end of the week.

The hearing came when a former Theranos executive who had been close to Holmes in the company’s final days told CNBC that management was discussing Holmes’ resignation as CEO on several occasions. For Holmes, however, “that was a non-runner”.

“If she had resigned, I think she would have saved herself a lot of legal danger,” said the former Theranos manager, who asked not to be named. “Everyone who knows Elizabeth knows that she saw herself as a company, and I don’t think she can see the company going on without her.”

Holmes left Stanford at 19 to start Theranos. By the time the company collapsed in 2018, she had a six-figure salary and a multi-billion dollar stake in the blood testing startup.

However, an investigation by the Wall Street Journal found that the technology didn’t work as Holmes claimed it did. Now she faces a dozen fraud charges for falsely claiming that Theranos technology can perform dozens of blood tests on a drop or two of blood. She pleaded not guilty.

Despite the chaos in the final months of her reign, Holmes believed Theranos could still be saved.

Holmes achieved a partial victory this week when the judge ruled that defenders can refer to Silicon Valley’s hype culture to explain why Holmes exaggerated the technology behind Theranos.

Categories
Health

This New Covid Vaccine May Carry Hope to the Unvaccinated World

This New Covid Vaccine Could Bring Hope to the Unvaccinated World

Anfang 2020 versuchten Dutzende wissenschaftlicher Teams, einen Impfstoff gegen Covid-19 herzustellen. Einige entschieden sich für bewährte Techniken wie die Herstellung von Impfstoffen aus abgetöteten Viren. Eine Handvoll Unternehmen setzen jedoch auf eine riskantere Methode, bei der noch nie ein zugelassener Impfstoff hergestellt wurde: den Einsatz eines genetischen Moleküls namens RNA.

Die Wette hat sich ausgezahlt. Die ersten beiden Impfstoffe, die aus klinischen Studien von Pfizer-BioNTech und Moderna erfolgreich hervorgegangen sind, bestanden beide aus RNA. Es stellte sich heraus, dass beide Wirksamkeitsraten so gut waren, wie ein Impfstoff nur sein konnte.

In den folgenden Monaten haben diese beiden RNA-Impfstoffe zig Millionen Menschen in rund 90 Ländern geschützt. Aber viele Teile der Welt, einschließlich derer mit steigenden Todesopfern, hatten kaum Zugang zu ihnen, auch weil sie in einem Tiefkühlschrank gehalten werden müssen.

Jetzt kann ein dritter RNA-Impfstoff dazu beitragen, diesen globalen Bedarf zu decken. Ein kleines deutsches Unternehmen namens CureVac steht kurz vor der Bekanntgabe der Ergebnisse seiner späten klinischen Studie. Bereits nächste Woche kann die Welt erfahren, ob der Impfstoff sicher und wirksam ist.

Das Produkt von CureVac gehört zu dem, was viele Wissenschaftler als zweite Welle von Covid-19-Impfstoffen bezeichnen, die die weltweite Nachfrage insgesamt senken könnten. Novavax, ein in Maryland ansässiges Unternehmen, dessen Impfstoff Coronavirus-Proteine ​​verwendet, wird voraussichtlich in den nächsten Wochen eine US-Zulassung beantragen. In Indien testet das Pharmaunternehmen Biological E einen weiteren Impfstoff auf Proteinbasis, der von Forschern in Texas entwickelt wurde. In Brasilien, Mexiko, Thailand und Vietnam starten Forscher Versuche für einen Covid-19-Schuss, der in Hühnereiern in Massenproduktion hergestellt werden kann.

Impfstoffexperten sind besonders gespannt auf die Ergebnisse von CureVac, da die Impfung einen wichtigen Vorteil gegenüber den anderen RNA-Impfstoffen von Moderna und Pfizer-BioNTech hat. Während diese beiden Impfstoffe in einer Tiefkühltruhe aufbewahrt werden müssen, bleibt der Impfstoff von CureVac im Kühlschrank stabil – was bedeutet, dass er die neu entdeckte Kraft von RNA-Impfstoffen leichter an schwer betroffene Teile der Welt liefern kann.

“Es ist weitgehend unter dem Radar verschwunden”, sagte Jacob Kirkegaard, Senior Fellow am Peterson Institute for International Economics in Washington, DC. Jetzt fügte er hinzu: “Sie sehen ziemlich gut positioniert aus, um den globalen Markt aufzuräumen.”

Für den Mitbegründer von CureVac, den Biologen Ingmar Hoerr, ist die Covid-19-Impfstoffstudie des Unternehmens der Höhepunkt einer Arbeit von einem Vierteljahrhundert mit RNA, einem Molekül, das dazu beiträgt, DNA in Proteine ​​umzuwandeln, die die Arbeit unserer Zellen erledigen. Als Doktorand an der Universität Tübingen in den 1990er Jahren injizierte Dr. Hoerr Mäusen RNA und stellte fest, dass die Tiere das von den Molekülen kodierte Protein herstellen konnten. Er war überrascht festzustellen, dass das Immunsystem der Mäuse Antikörper gegen die neuen Proteine ​​bildete.

Hier, dachte Dr. Hoerr, könnte dies die Grundlage für eine neue Art von Impfstoff sein. “Ich dachte, Wow, wenn das beim Menschen so funktioniert, dann haben wir eine völlig neue pharmazeutische Möglichkeit”, sagte er.

Zu dieser Zeit betrachteten nur wenige Wissenschaftler auf der Welt einen RNA-Impfstoff als ernsthafte Möglichkeit. Aber Befürworter dachten, es könnte die Medizin verändern. Theoretisch könnte man ein RNA-Molekül herstellen, um Menschen gegen jedes Virus zu immunisieren. Sie könnten sogar in der Lage sein, einen RNA-Impfstoff zur Heilung von Krebs zu entwickeln, wenn Sie ein RNA-Molekül herstellen könnten, das ein Tumorprotein codiert.

Im Jahr 2001 war Dr. Hoerr Mitbegründer von CureVac, um der Idee nachzujagen. In den ersten Jahren kämpfte das Unternehmen jedoch ums Überleben. Um das Licht an zu halten, wurden Aufträge von anderen Labors für maßgeschneiderte RNA-Moleküle entgegengenommen. Nebenbei bastelten die Wissenschaftler von CureVac an ihren eigenen Entwürfen für RNA-Impfstoffe.

Im Laufe der Zeit fanden sie subtile Verbesserungen an RNA-Impfstoffmolekülen, die dazu führten, dass Zellen mehr Proteine ​​produzierten. Je wirksamer die RNA ist, desto niedriger ist die Dosis, die sie für Impfstoffe benötigt.

Die Forscher von CureVac fanden auch heraus, wie die RNA-Moleküle in Fettblasen eingebracht werden können, um sie auf ihrem Weg zu den Zellen vor Zerstörung zu schützen. Und vielleicht am wichtigsten war, dass sie eine Form von RNA verwendeten, die bei relativ warmen Temperaturen stabil bleiben konnte. Anstatt eine Tiefkühltruhe zu benötigen, könnte der Impfstoff von CureVac gekühlt werden.

Mit der Zeit stiegen auch andere Unternehmen in das Geschäft mit RNA-Impfstoffen ein: BioNTech in Deutschland im Jahr 2008, dann Moderna in Boston im Jahr 2011. Ihre Experimente zeigten, dass diese Impfstoffe Tiere vor einer Vielzahl von Viren schützen können. Im Jahr 2013 injizierte CureVac Freiwilligen in der ersten klinischen Studie der Technologie gegen eine Infektionskrankheit einen Tollwut-RNA-Impfstoff.

CureVac und andere RNA-Impfstoffhersteller haben jahrelang daran gearbeitet, ihre Impfstoffe zu perfektionieren. Der erste Versuch von CureVac mit einem Tollwutimpfstoff zeigte, dass er sicher war, aber eine schwache Reaktion des Immunsystems hervorrief. Das Unternehmen hat diesen Impfstoff inzwischen umgerüstet, und die aktualisierte Version hat sich in frühen klinischen Studien als vielversprechend erwiesen. Aber andere Bemühungen scheiterten. Im Jahr 2017 gab CureVac bekannt, dass sein RNA-Impfstoff gegen Prostatakrebs den Patienten keine Vorteile bietet.

Trotz dieser Rückschläge hat sich das Unternehmen einen guten Ruf erworben. “Sie haben die Kriterien für wissenschaftlichen Scharfsinn, Geschwindigkeit, Umfang und Zugang erfüllt”, sagte Nicholas Jackson, Leiter der Impfstoffforschung und -entwicklung bei der Coalition for Epidemic Preparedness Innovations, einer Stiftung, die die Impfstoffforschung unterstützt. CEPI spendete CureVac 2019 34 Millionen US-Dollar, um die Entwicklung von RNA-Impfstoffen für zukünftige Pandemien zu unterstützen.

Aktualisiert

5. Mai 2021, 15:31 Uhr ET

Als die Coronavirus-Pandemie auftrat, sprangen CureVac, BioNTech und Moderna ein, um RNA-Impfstoffe herzustellen. Aber BioNTech und Moderna haben sich bald durchgesetzt, auch dank tief in die Tasche gesteckter Verbündeter. BioNTech hat sich mit dem Pharmagiganten Pfizer zusammengetan, während Moderna mit den National Institutes of Health zusammenarbeitete und im Rahmen der Operation Warp Speed ​​eine Milliarde Dollar von der US-Regierung erhielt.

CureVac blieb zurück. CEPI stellte dem Unternehmen 15 Millionen US-Dollar zur Verfügung, aber CureVac würde weit mehr benötigen. “Wenn Sie dies tun, brauchen Sie eine beträchtliche Menge Geld”, sagte Franz-Werner Haas, der Geschäftsführer von CureVac, in einem Interview. “Und die beträchtliche Menge an Bargeld war nicht da.”

Im März 2020 berichteten deutsche Zeitungen, dass Präsident Donald J. Trump CureVac 1 Milliarde US-Dollar angeboten hatte, um seine Aktivitäten in die USA zu verlagern. CureVac lehnte die Berichte ab, aber der Geschäftsführer ging plötzlich, um von Dr. Haas ersetzt zu werden.

Die Forscher von CureVac haben ihre begrenzten Ressourcen weiterentwickelt und ein RNA-Molekül entwickelt, das für ein Protein kodiert, das sich auf der Oberfläche des Coronavirus befindet und als Spike bezeichnet wird. Experimente an Hamstern zeigten, dass es die Tiere vor dem Virus schützen kann.

Im Juni investierte die Bundesregierung 300 Millionen Euro in das Covid-19-Research von CureVac, weitere Investoren folgten bald. Nach vielversprechenden Daten aus frühen Sicherheitsstudien startete das Unternehmen im Dezember seine letzte sogenannte Phase-3-Studie, in der 40.000 Freiwillige in Europa und Lateinamerika rekrutiert wurden. Das Unternehmen wird einen ersten Blick auf die Daten werfen, wenn 56 Freiwillige Covid-19 entwickeln. Wenn die meisten von ihnen in der Placebo-Gruppe und nur wenige in der geimpften Gruppe sind, ist dies ein Beweis dafür, dass der Impfstoff funktioniert.

Dr. Haas sagte, er rechne damit, diese Daten bis Mitte Mai zu haben. Es gibt keine Möglichkeit, im Voraus zu wissen, wie es CureVac ergeht. Angesichts der Leistung anderer RNA-Impfstoffe und der frühen Ergebnisse von CureVac haben einige Wissenschaftler hohe Erwartungen.

“Ich wäre nur wirklich überrascht, wenn es nicht gut funktionieren würde”, sagte John Moore, Virologe bei Weill Cornell Medicine in New York, der mit CureVac an einem RNA-basierten Impfstoff gegen HIV zusammengearbeitet hat

Dennoch steht der Impfstoff von CureVac vor einer Herausforderung, die Pfizer und Moderna nicht hatten: neue Varianten, die möglicherweise seine Wirksamkeit beeinträchtigen können. Experimente an Mäusen haben gezeigt, dass der Impfstoff gut gegen die B.1.351-Variante wirkt, die erstmals in Südafrika aufgetaucht ist.

Im vergangenen Jahr hat CureVac mit einer Reihe großer Unternehmen zusammengearbeitet, um die Produktion seines Covid-Impfstoffs zu steigern, falls die klinischen Studien gut verlaufen sollten. Das Unternehmen verhandelte außerdem mit der Europäischen Union einen Vertrag über 225 Millionen Dosen sowie die Option, in den folgenden Monaten weitere 180 Millionen Dosen hinzuzufügen.

Jetzt ist jedoch nicht klar, wer den CureVac-Impfstoff erhalten könnte, wenn er nächsten Monat verfügbar sein wird. Im Januar erteilte die Europäische Union einem Impfstoff von AstraZeneca die Notfallgenehmigung und plante, sich für den größten Teil seiner Versorgung auf dieses Unternehmen zu verlassen. Aber AstraZeneca blieb drastisch hinter seinen Lieferversprechen zurück und veranlasste den Block, sich mit einer Klage zu rächen.

Im April hat die Europäische Union dieses Defizit endgültig behoben und mit Pfizer und BioNTech verhandelt, um bis 2023 1,8 Milliarden Dosen ihres Impfstoffs zu erhalten. Aufgrund dieser Vereinbarung haben sich Analysten gefragt, wie viel Nachfrage nach CureVac noch bestehen wird.

“Sie werden das Boot auf den großen Märkten der fortgeschrittenen Wirtschaft vermissen”, sagte Dr. Kirkegaard. “Die USA, Europa und Japan werden mit diesen Moderna- und Pfizer-Impfstoffen weitgehend geimpft.”

Dr. Haas konterte, dass die meisten Dosen des Blocks von Pfizer-BioNTech erst im nächsten Jahr kommen werden. “CureVac sieht sich als wichtiger Akteur bei der Beendigung der Covid-19-Pandemie in Europa und anderswo”, sagte er.

CureVac wird aber auch mit einem weltweiten Mangel an Rohstoffen zu kämpfen haben, die für RNA-Impfstoffe benötigt werden. Das Defizit ist für das Unternehmen besonders akut, da die Importe aus den USA durch das Defence Production Act begrenzt sind. Im Gegensatz zu Pfizer-BioNTech oder Moderna verfügt CureVac über keine US-Einrichtungen.

“Das US Defence Production Act war ein Faktor, der unseren Zugang zu einigen Materialien und Vorräten beeinflusste”, sagte Dr. Haas. “Wir gehen jedoch derzeit nicht davon aus, dass dies unsere Produktionsprognosen für den Rest des Jahres 2021 und darüber hinaus wesentlich beeinflussen wird.”

Ursula von der Leyen, Präsidentin der Europäischen Kommission, sagte, wenn der CureVac-Impfstoff funktionieren würde, wäre er dank zweier Vorteile in der Mischung: Es handelt sich um einen mRNA-Impfstoff, der in Europa hergestellt wurde. Es ist auch möglich, dass einzelne europäische Nationen Nebengeschäfte mit dem Unternehmen abschließen.

Milliarden anderer Menschen in Ländern mit niedrigem und mittlerem Einkommen haben noch keinen Impfstoff erhalten, und Experten sagen, dass CureVac einen Teil ihrer Nachfrage befriedigen könnte. “Wir brauchen weltweit immer noch viel Impfstoff”, sagte Florian Krammer, Virologe an der Icahn School of Medicine am Mount Sinai in New York. “Ich denke, viele Menschen können davon profitieren.”

Die Impfstoffe von Moderna und Pfizer-BioNTech sind in Entwicklungsländern aufgrund der zum Einfrieren dieser Impfstoffe erforderlichen Ausrüstung und Stromversorgung nur schwer zu vertreiben. Der RNA-Impfstoff von CureVac kann bei 41 Grad Fahrenheit mindestens drei Monate lang stabil bleiben und vor der Verwendung 24 Stunden lang bei Raumtemperatur stehen.

“Die Stabilität ist ein echter Vorteil”, sagte Dr. Jackson. CEPI befindet sich “in sehr aktiven Gesprächen” mit CureVac über die Verteilung des Impfstoffs des Unternehmens über Covax, eine Initiative zur Verteilung von Impfstoffen an Länder mit niedrigem und mittlerem Einkommen.

CureVac entwickelt aber auch eine neue Generation von Impfstoffen mit dem Ziel, schließlich auf den Märkten in den USA und anderen reichen Ländern Fuß zu fassen. Da für seine potente RNA nur eine geringe Dosis erforderlich ist, könnte das Unternehmen möglicherweise Impfstoffe für verschiedene Varianten herstellen und diese in einem einzigen Schuss mischen.

Solche Möglichkeiten sind jedoch bedeutungslos, bis CureVac nachweisen kann, dass sein Impfstoff funktioniert. Mary Warrell, eine Impfstoffforscherin an der Universität von Oxford, zögert, vor diesem Meilenstein über das Schicksal des Impfstoffs zu spekulieren.

“Vorhersagen während dieser Pandemie waren selten rentabel”, warnte sie.

Matina Stevis-Gridneff trug zur Berichterstattung bei.

Categories
Health

Vaccinated individuals who had Covid might have extra safety in opposition to variants

Vaccinated people who had Covid may have more protection against variants

Dr. Anthony Fauci, director of the National Institute for Allergies and Infectious Diseases, speaks during a press conference at the White House in the James Brady Press Briefing Room of the White House on January 21, 2021 in Washington, DC.

Alex Wong | Getty Images

People who had Covid-19 and were later vaccinated may have more protection from highly contagious variants, said White House chief medical officer Dr. Anthony Fauci, on Wednesday.

Fauci cited a study published in late April that found that people with previous coronavirus infections had better immune responses to B.1.1.7 and B.1.351, first used in the UK and the South, after a dose of the Pfizer BioNTech vaccine identified variants of Africa compared to those that did not have Covid.

He cited an additional study published online that has not yet been peer-reviewed. It found that people with previous infections who were later fortified with two doses of an mRNA vaccine had “increased protection” against variants.

The studies provide more evidence of the benefits of vaccination, Fauci said.

“Vaccines are very effective,” Fauci said during a Covid briefing at the White House. “You are better than the response you get from a natural infection.”

His comments stem from the Biden government’s drive to partially vaccinate 70% of adults in the United States and 160 million adults fully by July 4th. This is a date the government hopes will mark a turning point in the pandemic.

Over the past few weeks, the pace of people getting their first doses of vaccine has slowed, despite U.S. health officials say they’re working to improve access to the shots and encourage more reluctant Americans to get vaccinated.

Earlier Wednesday, the Centers for Disease Control and Prevention released a new report forecasting Covid-19 cases to rise through May before falling sharply into July as vaccinations reduce infections.

Highly contagious variants, namely the highly contagious B.1.1.7 identified for the first time in Great Britain, remain a wild card, according to US health authorities. They urge Americans to get vaccinated and take safety measures against pandemics.

“We are seeing that our current vaccines protect against the pollutants circulating in the country. Put simply, the sooner more people are vaccinated, the sooner we will all get back to normal,” said CDC Director Dr. Rochelle Walensky during the press conference.

Categories
Health

Working Rooms Go Below the Knife

Operating Rooms Go Under the Knife

Of all imaging devices, the only one that is generally unsuitable for the operating room is the one that, due to its size, is needed for magnetic resonance imaging – commonly known as MRI. As a result, Ms. Saba said, some hospitals essentially station her next to an operating room in case an MRI is needed. A separate room offers an additional efficiency advantage, as the devices can also be used for non-surgical patients.

Ceilings are not overlooked. Monitors that free up valuable floor space are often attached to ceiling-mounted cantilevers that can have multiple arms and also serve as conduits for gases needed for anesthesia. Ultraviolet cleaning systems that remove bacteria and viruses can be anchored in the ceilings to aid in disinfection. The space above the ceiling is often larger to accommodate a range of cables and other electronic equipment, in addition to piping with sophisticated air filtration systems.

Access to the space above the ceiling as well as behind the walls has become important so that technical problems can be investigated and fixed in hours, rather than closing a room for lengthy repairs. For example, some hospitals are currently considering prefabricated stainless steel wall systems for their operating rooms because they are both easier to clean and easier to remove if the electronics hidden behind the hiding place break, Ms. Saba said.

Other important factors are lighting and noise. When it comes to increasingly common laparoscopic surgeries, monitors that surgeons guide are lit, but the overhead lights can be turned off to reduce glare, said Dr. Hawn.

That “can be a little dangerous because it can be pretty dark and people bump into or trip over things,” she added. “We now have the green light, which means we can see a sharp image on the monitors without the glare you get from the white light.”

Noise is distracting at best, but it has physical effects such as high blood pressure, especially on employees who are exposed over a long period of time. High decibel levels are “associated with increased communication difficulties, which are the greatest source of avoidable errors in the hospital environment,” said John Medina, associate professor in the Department of Bioengineering at the University of Washington, in an email.

Categories
Health

Singapore’s Covid scenario might begin to enhance in weeks: Professor

Singapore's Covid situation may start to improve in weeks: Professor

SINGAPORE – Singapore is facing the largest local outbreak of Covid-19 infection in months. However, according to Dale Fisher, chairman of the World Health Organization’s (WHO) Global Outbreak Alert and Response Network, the situation could improve in the coming weeks.

“We believe we can break the transmission chains,” he told CNBC’s Street Signs Asia on Wednesday.

“With quite a sophisticated and thorough contact tracing, along with quarantining the contacts and isolating the cases, I would have confidence that the situation will improve in the next few weeks,” said Fisher, who is also a professor at Yong Loo Lin School of Medicine at the National University of Singapore.

Singapore’s new cases in the community rose from 11 the week before to 64 in the past week, the Ministry of Health announced on Tuesday.

The country’s multi-ministry task force announced Tuesday that stricter restrictions would be in place from May 8-30. The Straits Times index fell 1.04% on Wednesday afternoon.

Variants in the community

Authorities also said the “double mutant” variant of Covid – first detected in India – was found among locally transmitted cases. This B.1.617 strain is believed in part to be to blame for India’s rising caseload, which has marginalized its healthcare system as hospitals run out of beds and oxygen.

Fisher said it was difficult to determine how much of an impact each variant can have on how the virus is transmitted.

While there is “good evidence” that many variants “increased portability”, this is not the only factor.

“It’s also about all of the different measures that are in place and actually those measures work. It’s just … this version of the virus is less forgiving of violations,” he said.

It’s about shutting down clusters, stopping transmission chains and living with (the virus) instead of having a … blunt shutdown.

Dale Fisher

Professor at the National University of Singapore.

He noted that some cases were confirmed after the 14-day quarantine was completed. Singapore has extended the quarantine period for travelers from higher risk countries to 21 days.

However, it’s not clear whether the incubation period is longer for variants of the virus, said Fisher, who added that there may also be false negative Covid test results – meaning that a person is actually sick with the disease but the test does indicate that she is not infected.

“Trust” in Singapore

Still, he said he has “a lot of confidence” in Singapore’s systems and believes the country is taking the right approach by not going into lockdown.

“It’s about shutting down clusters, stopping chains of transmission and living with (the virus) instead of having a … blunt shutdown,” he said. “We are aware of the social and economic consequences.”

On vaccinations, Fisher said Singapore likely leads the rest of Asia in terms of the proportion of its population that received at least one shot. “I think we’re getting there steadily,” he said. “Very high levels of nationwide vaccination are expected by October.”

As of April 18, more than 2.2 million doses of the vaccine had been administered in Singapore, the ministry said. The country reported 16 new cases on Wednesday, bringing the total to 61,268.

Categories
Health

$100 as Incentive to Get a Shot? Experiment Suggests It Can Pay Off.

$100 as Incentive to Get a Shot? Experiment Suggests It Can Pay Off.

What’s the best way to convince the millions of Americans who are not yet vaccinated against Covid-19 to get their shots?

The reassuring public service announcements about the safety and effectiveness of the vaccine have increased. But more and more people are realizing that it takes more than information to influence those who hesitate.

In recent randomized survey experiments by the UCLA Covid-19 Health and Politics Project, two seemingly strong incentives emerged.

About a third of the unvaccinated population said paying cash would make them more likely to get a shot. This suggests that some governors are on the right track. For example, West Virginia Governor Jim Justice recently announced that the state would give young people $ 100 bonds if they were vaccinated.

Similarly, willingness to take vaccines increased for those asked about a vaccine if it meant they did not have to wear a mask or social distance in public, compared to a group who were told they still did Do these things.

The UCLA project, which is still ongoing, has surveyed more than 75,000 people in the past 10 months. This collaboration between doctors and social scientists at UCLA and Harvard measures people’s pandemic experiences and attitudes in political and economic terms, while also demonstrating their physical and mental health and wellbeing.

In order to assess the effectiveness of different messages in vaccine intake, the project randomly assigns non-vaccinated respondents to groups who see different information about the benefits of vaccination. Random assignment makes the composition of each group similar. This is important because researchers can conclude that differences between groups in people’s intentions to get vaccinated are due to the messages each group saw, rather than other underlying attributes.

Last October, one group saw messages framing the benefits of vaccination in a selfish way – “It will protect you” – while others saw messages framing the benefits in a more social way: “It will protect you and those around you. “The subtle change did little; About two-thirds of the people in both groups said they intend to take the pictures.

Another experiment examined the persuasiveness of certain endorsements. Proponents included prominent figures such as then President Donald J. Trump and Dr. Anthony Fauci, but also more personal medical sources like “Your Doctor”.

Most of the effects were minor. The statement by their doctor, pharmacist, or insurer that the vaccine was safe and effective had no discernible impact on vaccination intentions, although confirmation from Dr. Fauci increased the likelihood of admission by about six percentage points.

Endorsement by political figures sparked strong reactions from the partisans, with Mr Trump’s endorsement decreasing acceptance among Democrats in 2020 and increasing acceptance for Republicans to a lesser extent. President Biden’s approval reduced Republican acceptance in 2021. There was evidence in 2021 that Trump approval could increase Republican acceptance, but the impact was much less than when he was in office.

Updated

May 4, 2021, 3:12 p.m. ET

Last month, researchers randomly selected unvaccinated respondents to see news about financial incentives. Some people have been asked about the chances of getting a vaccine if it came with a cash payment of $ 25. other people were asked if they wanted to get $ 50 or $ 100.

About a third of the unvaccinated population said paying cash would make them more likely to get a shot. The benefits were greatest for those in the group who received $ 100, which increased willingness (34 percent said they would get vaccinated) by six points over the $ 25 group.

The effect was greatest for unvaccinated Democrats, 48 ​​percent of whom said they were more likely to be vaccinated if provided with a $ 100 payment.

Some previous research shows that paying for vaccines can backfire, and in the UCLA study, about 15 percent of people who were not vaccinated report a decline in vaccination due to payments. But at this later stage in a vaccination campaign – when attention is now on hesitation – the net benefits seem to be leaning towards payment.

The incentive to stop wearing a mask and to distance oneself socially in public also had a strong result. On average, mask loosening and social distancing guidelines increased the likelihood of vaccine intake by 13 points. The Republicans saw the biggest gains, with an 18-point increase in vaccination readiness.

These results show both the difficulty of getting the remaining unvaccinated people to clinics and the promise of efforts aimed at that. While most of the messaging effects have been minor, cash payments seem to motivate the Democrats, and the relaxation of the warning guidelines seems to be working for the Republicans. (The CDC recently relaxed guidelines for wearing masks outdoors for vaccinated individuals.)

The movement towards vaccinations among the reluctant may increase over time and as people observe the effects of vaccination on those who were vaccinated first. When we asked unvaccinated people why they didn’t try to get a shot, 38 percent said they were concerned about the side effects and 34 percent said they didn’t think the vaccine was safe. Persuasion that shows the brevity or absence of side effects and the safety of the vaccination can allay these fears. Still, a quarter of those unvaccinated say they just don’t trust the government’s motives, and 14 percent say Covid-19 does not pose a threat to them. These people will be harder to convince.

Data from the project shows how eager Americans are to get back to normal activities. Among people who work outside of their home, 76 percent of respondents said they want to go back to the way they did before the pandemic, and 66 percent said it would be safe to do so by April. These numbers are similar regardless of vaccination status.

The April survey also asked people what social activities they had done in the past two weeks. About 30 percent said they eat in a restaurant. 17 percent said they had attended a personal religious meeting. and 11 percent met with a group of more than 10 non-family members. Almost everything took place inside.

The vaccination rates for people doing these activities largely reflect the rates in the general population, which means that not everyone who is on the go has received the vaccine.

32 percent of restaurants said they were fully vaccinated (53 percent said they weren’t vaccinated at all). The balance between people attending face-to-face religious gatherings was roughly the same – 41 percent said they were fully vaccinated and 41 percent said they were not vaccinated at all.

Most people at social events with more than 10 non-family members were not fully vaccinated, although the proportion of people vaccinated was higher at indoor gatherings (40 percent) than at outdoor events (27 percent).

People venture into social spaces, but around them unvaccinated people are still more numerous than those vaccinated in many places – and vaccination rates are slowing down. Reversing this trend takes more than passionate pleas from politicians, friends, or medical professionals. There may be a need to deliver real rewards beyond the health benefits of the vaccine.

Lynn Vavreck, Marvin Hoffenberg Professor of American Politics and Public Order at UCLA, is a co-author of “Identity Crisis: The 2016 Presidential Campaign and the Controversy for America”. Follow her on Twitter at @vavreck. She is also the Principal Researcher on the UCLA Covid-19 Health and Policy Project, with Arash Naeim, Neil Wenger and Annette Stanton of the David Geffen School of Medicine at UCLA and Karen Sepucha of the Massachusetts General Hospital and Harvard Medical School.

Categories
Health

U.S. delivery and fertility charges dropped to a different report low in 2020, CDC says

U.S. birth and fertility rates dropped to another record low in 2020, CDC says

A newborn is cuddled by its mother while it sleeps.

Tim Clayton | Corbis News | Getty Images

According to new data from the National Center for Health Statistics from the Centers for Disease Control and Prevention, birth and fertility rates in the US fell to another record low in 2020 as births fell to their lowest level since 1979 for the sixth consecutive year.

The number of births in the US declined 4% last year from 2019, double the average annual rate of 2% since 2014, the CDC said in preliminary birth data released on Wednesday. Overall and general fertility rates have also declined 4% since 2019, hitting record lows. The US birthrate is so low that the nation is “below replacement levels,” meaning more people die than are born every day, the CDC said.

While the agency did not directly attribute the overall decline in births to the Covid-19 pandemic, it did research the birth rates of New York women who gave birth to their babies outside the five boroughs during the peak of the US outbreak

Women fled the city to give birth between March and November last year. Out-of-town births among NYC residents peaked more than 10% in both months in April and May – an increase of more than 70% year over year. Among white women, the proportion of out-of-town births in 2020 was 2.5 times higher than in 2019. Out-of-town births among black and Hispanic women were significantly lower, taking only two of the months of last year to.

Overall, births for Hispanic women decreased by 3% from 2019 to 2020, and for white and black women by 4%.

Teenage birth rates fell significantly, with births dropping 6% for 15-17 year olds and 7% for 18-19 year olds, both hitting record lows.

Birth rates among women aged 20 to 24 and 25 to 29 years declined 6% and 4%, respectively, to hit both lows. Birth rates in women aged 30 to 34 and 35 to 39 years old fell 4% and 2%, respectively, but did not hit record lows, according to CDC data.

The birth rates for women aged 40 and over decreased 44% from 2019, but the birth rates for women aged 45 and over remained unchanged. according to CDC.

The data was based on population estimates derived from the July 1 2010 census and the number of all birth records received and processed by the National Center for Health Statistics on February 11. The records represent nearly 100% of the registered births in 2020.

Some experts say that a decline in birth rates could represent a lack of vital resources such as housing and food in this population group, with correlations between increases in unemployment rates and decreases in birth rates. The future economic impact of a drop in birth rates continues to be debated.